BioN­Tech to pay $200M up­front in CT­LA-4 an­ti­body de­vel­op­ment, com­mer­cial­iza­tion deal

BioN­Tech is branch­ing out in­to CT­LA-4 as part of a deal with the crew be­hind On­coIm­mune.

BioN­Tech and On­coC4 put out word Mon­day that they had reached an ex­clu­sive deal to co-de­vel­op and co-com­mer­cial­ize On­coC4’s mon­o­clon­al an­ti­body can­di­date for a va­ri­ety of can­cer in­di­ca­tions.

The deal will see BioN­Tech pay­ing On­coC4, a spin­out of On­coIm­mune, $200 mil­lion up­front for ONC-392, On­coC4’s an­ti-CT­LA-4 can­di­date — plus undis­closed mile­stone pay­ments and tiered roy­al­ties. On top of that, the com­pa­nies will joint­ly de­vel­op the drug and split de­vel­op­ment costs in sev­er­al sol­id tu­mor in­di­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER